Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance to gemcitabine, the first line chemotherapeutic approach. Thus, there is a strong need for novel therapies, targeting more directly the molec...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabretta, Sara, Bielli, Pamela, Passacantilli, Ilaria, Pilozzi, Emanuela, Fendrich, Volker, Capurso, Gabriele, Delle Fave, Gianfranco, Sette, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650269/
https://www.ncbi.nlm.nih.gov/pubmed/26234680
http://dx.doi.org/10.1038/onc.2015.270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650269/
https://www.ncbi.nlm.nih.gov/pubmed/26234680
http://dx.doi.org/10.1038/onc.2015.270

Ejemplares similares